Literature DB >> 15907740

Intake of vitamin E, vitamin C, and carotenoids and the risk of Parkinson's disease: a meta-analysis.

Mahyar Etminan1, Sudeep S Gill, Ali Samii.   

Abstract

We studied the effect of vitamin C, vitamin E, and beta carotene intake on the risk of Parkinson's disease (PD). We did a systematic review and meta-analysis of observational studies published between 1966 and March 2005 searching MEDLINE, EMBASE, and the Cochrane Library. Eight studies were identified (six case-control, one cohort, and one cross-sectional). We found that dietary intake of vitamin E protects against PD. This protective influence was seen with both moderate intake (relative risk 0.81, 95% CI 0.67-0.98) and high intake (0.78, 0.57-1.06) of vitamin E, although the possible benefit associated with high intake of vitamin E was not significant. The studies did not suggest any protective effects associated with vitamin C or beta carotene. We conclude that dietary vitamin E may have a neuroprotective effect attenuating the risk of PD. These results require confirmation in randomised controlled trials.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15907740     DOI: 10.1016/S1474-4422(05)70097-1

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  68 in total

1.  The association between Mediterranean diet adherence and Parkinson's disease.

Authors:  Roy N Alcalay; Yian Gu; Helen Mejia-Santana; Lucien Cote; Karen S Marder; Nikolaos Scarmeas
Journal:  Mov Disord       Date:  2012-02-07       Impact factor: 10.338

2.  Reporting of systematic reviews of micronutrients and health: a critical appraisal.

Authors:  Mei Chung; Ethan M Balk; Stanley Ip; Gowri Raman; Winifred W Yu; Thomas A Trikalinos; Alice H Lichtenstein; Elizabeth A Yetley; Joseph Lau
Journal:  Am J Clin Nutr       Date:  2009-02-25       Impact factor: 7.045

3.  A nutraceutical a day may keep the doctor away. Consumers are turning increasingly to food supplements to improve well-being when pharmaceuticals fail.

Authors:  Vicki Brower
Journal:  EMBO Rep       Date:  2005-08       Impact factor: 8.807

Review 4.  Disease modification in Parkinson's disease.

Authors:  Claire Henchcliffe; W Lawrence Severt
Journal:  Drugs Aging       Date:  2011-08-01       Impact factor: 3.923

5.  Polymer brain-nanotherapeutics for multipronged inhibition of microglial α-synuclein aggregation, activation, and neurotoxicity.

Authors:  Neal K Bennett; Rebecca Chmielowski; Dalia S Abdelhamid; Jonathan J Faig; Nicola Francis; Jean Baum; Zhiping P Pang; Kathryn E Uhrich; Prabhas V Moghe
Journal:  Biomaterials       Date:  2016-10-04       Impact factor: 12.479

6.  Prospective study of dietary pattern and risk of Parkinson disease.

Authors:  Xiang Gao; Honglei Chen; Teresa T Fung; Giancarlo Logroscino; Michael A Schwarzschild; Frank B Hu; Alberto Ascherio
Journal:  Am J Clin Nutr       Date:  2007-11       Impact factor: 7.045

7.  Single-cell lipidomics: characterizing and imaging lipids on the surface of individual Aplysia californica neurons with cluster secondary ion mass spectrometry.

Authors:  Melissa K Passarelli; Andrew G Ewing; Nicholas Winograd
Journal:  Anal Chem       Date:  2013-02-04       Impact factor: 6.986

8.  Differential effects of black versus green tea on risk of Parkinson's disease in the Singapore Chinese Health Study.

Authors:  Louis C Tan; Woon-Puay Koh; Jian-Min Yuan; Renwei Wang; Wing-Lok Au; June H Tan; Eng-King Tan; Mimi C Yu
Journal:  Am J Epidemiol       Date:  2007-12-20       Impact factor: 4.897

9.  Neuroprotective therapy in Parkinson's disease: current status and new directions from experimental and genetic clues.

Authors:  William Lin; Un Jung Kang
Journal:  J Clin Neurol       Date:  2005-10-20       Impact factor: 3.077

10.  The therapeutic potential of LRRK2 and alpha-synuclein in Parkinson's disease.

Authors:  Saurabh Sen; Andrew B West
Journal:  Antioxid Redox Signal       Date:  2009-09       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.